biostudies-literatureUnknown12Hiremath CS<h4>Objectives</h4>The durability and performance of bioprosthetic valves are pivotal in managing valvular heart disease (VHD). This 5-year follow-up study evaluated the long-term clinical safety, haemodynamic performance, and quality-of-life (QoL) outcomes of the Dafodil™ pericardial bioprosthesis in patients undergoing aortic or mitral valve replacement (AVR/MVR).<h4>Methods</h4>In this prospective, multicenter, first-in-human trial conducted across 19 Indian centers, 136 patients with advanced VHD (67 AVR, 69 MVR) were enrolled. Key endpoints were evaluated over 5 years.<h4>Results</h4>The mean age of the patients in the AVR and MVR cohorts was 60.2 ± 8.3 years and 49.7 ± 14.4 years, respectively. A total of 124 patients (61 AVR, 63 MVR) completed the 5-year follow-up. In the AVR cohortFrontiers in cardiovascular medicine1672315https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828671biostudies-literatureOutcomes of aortic and mitral valve replacement with Dafodil™ pericardial bioprosthesis over 5-years: Dafodil™-1 trial.PMC12828671S J CGarg AGrover VPorwal MSethuratnam RBhat SThakur NTChaudhary SKShastri NJain ASancheti AHiremath CSMishra YKRajput SSPadmanabhan CSarkar BKNaik DGupta NVaijyanath PGupta VKMaslekar ASingh Meharwal ZfalseOutcomes of aortic and mitral valve replacement with Dafodil™ pericardial bioprosthesis over 5-years: Dafodil™-1 trial.<h4>Objectives</h4>The durability and performance of bioprosthetic valves are pivotal in managing valvular heart disease (VHD). This 5-year follow-up study evaluated the long-term clinical safety, haemodynamic performance, and quality-of-life (QoL) outcomes of the Dafodil™ pericardial bioprosthesis in patients undergoing aortic or mitral valve replacement (AVR/MVR).<h4>Methods</h4>In this prospective, multicenter, first-in-human trial conducted across 19 Indian centers, 136 patients with advanced VHD (67 AVR, 69 MVR) were enrolled. Key endpoints were evaluated over 5 years.<h4>Results</h4>The mean age of the patients in the AVR and MVR cohorts was 60.2 ± 8.3 years and 49.7 ± 14.4 years, respectively. A total of 124 patients (61 AVR, 63 MVR) completed the 5-year follow-up. In the AVR cohort2025-01-01T00:00:00Z20252026-06-13T05:17:23.548Z2026-06-13T03:08:53.62ZS-EPMC128286714158428410.3389/fcvm.2025.1672315